A Trial to Determine the Safety and Anti-tumor Activity Profile of the Combination of Cetuximab and Concomitant Cisplatin Plus 5-Fluorouracil (5-FU) in Subjects With Recurrent and/or Metastatic Squamous Cell Carcinoma in Head and Neck

NCT01177956 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

73

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

BIOLOGICAL: Cetuximab
DRUG: Cisplatin
DRUG: 5-Fluorouracil

Sponsor

Merck KGaA, Darmstadt, Germany